| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $10.23B | +27.7% |
| Cost of Revenue | $6.51B | +28.3% |
| R&D Expense | $441.7M | +25.4% |
| SG&A Expense | $1.62B | +17.7% |
| Operating Income | $1.83B | +33.8% |
| Interest Expense | $86.1M | -42.8% |
| Pre-tax Income | $1.74B | +127.6% |
| Income Tax | $409.1M | +51.7% |
| Net Income | $1.33B |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.73B | +40.8% |
| Accounts Receivable | $3.11B | +31.6% |
| Inventory | $1.46B | +17.0% |
| Current Assets | $6.82B | +33.7% |
| Total Assets | $12.21B | +33.7% |
| Current Liabilities | $4.41B | +42.3% |
| Long-term Debt | $2.91B | -0.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $2.11B | +60.2% |
| Capital Expenditures | $220.0M | +31.7% |
| Investing Cash Flow | -$1.50B | -644.1% |
| Financing Cash Flow | -$72.3M | +88.9% |
| Free Cash Flow | $1.89B | +64.3% |
| +168.8% |
| EPS (Basic) | $3.49 | +164.4% |
| EPS (Diluted) | $3.41 | +166.4% |
| Total Liabilities |
| $8.27B |
| +23.5% |
| Stockholders' Equity | $3.94B | +61.9% |